Gemcitabine + Paxalisib
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Atypical Teratoid/Rhabdoid Tumor
Conditions
Recurrent Atypical Teratoid/Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS
Trial Timeline
May 1, 2026 → Dec 31, 2036
NCT ID
NCT07447076About Gemcitabine + Paxalisib
Gemcitabine + Paxalisib is a phase 2 stage product being developed by Pacific Biosciences for Recurrent Atypical Teratoid/Rhabdoid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07447076. Target conditions include Recurrent Atypical Teratoid/Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Atypical Teratoid/Rhabdoid Tumor were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07447076 | Phase 2 | Recruiting |
Competing Products
20 competing products in Recurrent Atypical Teratoid/Rhabdoid Tumor